Bioprocessing of Viral Vectors and Vaccines

病毒载体和疫苗的生物加工

• 批准号: CRC-2021-00032
• 负责人: Kamen, Amine
• 金额: $ 14.57万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Canada Research Chairs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=744429
• 关键词: Bioprocessing; Viral; Vectors; Vaccines

The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering.- Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines.- Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases.Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.

主席在上一任期内取得的主要成就包括： - 将流感种子库存的生成速度从几个月缩短到几周，以便利用细胞培养技术和逆向工程快速生产疫苗，以应对大流行情况。 - 生产工艺的开发和技术转让用于预防新城疫感染的腺病毒载体疫苗，以保护埃塞俄比亚的牲畜。 - 在悬浮液和无血清培养基中操作的 Vero 细胞系生产平台的先进工艺开发，用于生产针对埃博拉、HIV 和 SARS-CoV-2 候选疫苗的重组水泡性口炎病毒载体疫苗。 - 能力建设和高素质人员 (HQP) ）在加拿大和国外进行培训，以支持应对新出现和重新出现的传染病的准备计划。在这些有影响力的成就的基础上，目前工业界正在利用这些成果来加速开发针对新出现和重新出现的传染病的载体疫苗COVID-19大流行是拟议的CRC病毒载体和疫苗生物过程科学与技术一级研究计划，重点是复杂生物系统的逆向工程和细胞/病毒相互作用的动力学，以设计先进的制造工艺，以实现安全、有效和具有成本效益的用于体内基因编辑的疫苗和输送系统。一种系统方法，集成了 1) 病毒和细胞生物平台的基因组规模重新设计，2) 持续过程加速和强化，3) 过程分析技术和数据科学，以支持高价值药物的交付，以应对新兴和重新出现的传染病。该研究计划建立在与工业和机构合作伙伴的长期合作基础上，以支持新技术的转化并支持高价值病毒产品的商业化。该计划还旨在为总部提供扎实的培训，以满足加拿大生物制造行业的需求，并在先进疫苗制造的战略领域建立持续的能力。